OTCMKTS:TRLPF Acerus Pharmaceuticals (TRLPF) Stock Forecast, Price & News $0.22 0.00 (0.00%) (As of 07/21/2023) Add Compare Share Share Today's Range$0.22▼$0.2250-Day Range$0.22▼$0.2252-Week Range$0.08▼$0.34VolumeN/AAverage Volume5,474 shsMarket Capitalization$56.90 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsHeadlinesProfileChartCompetitorsHeadlines About Acerus Pharmaceuticals (OTCMKTS:TRLPF) StockAcerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Elegant vaginal moisturizer, which provides comfort to women suffering from vaginal dryness; and Elegant pH, a pH balanced vaginal product; Gynoflor, an ultra-low dose vaginal estrogen combined with a probiotic for the treatment of vaginal atrophy, restoration of vaginal flora, and treatment of certain vaginal infections; and Tefina, a clinical stage product for women with female sexual dysfunction. Acerus Pharmaceuticals Corporation sells products through its salesforce in Canada; and through a network of licensed distributors in the United States and internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.Read More TRLPF Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TRLPF Stock News HeadlinesJanuary 1, 2023 | seekingalpha.com2023 A Big Year For Testosterone: AbbVie And ANI Pharmaceuticals Best Positioned To BenefitAugust 9, 2022 | financialpost.comAcerus Reports Second Quarter 2022 Financial ResultsSeptember 27, 2023 | Altimetry (Ad)DOD Consultant's big 2024 prediction looks to be coming trueEarlier this year, a Department of Defense (DOD) consultant went public with a big prediction…About how a surprising 2024 event would dramatically affect you and your money. The most recent figures (published June 9th 2023) indicate he’s very likely to be right. Get the facts—learn how to prepare. Full analysis available free of charge here…March 15, 2022 | financialpost.comAcerus Reports Fourth Quarter and Full Year 2021 Financial ResultsMay 10, 2021 | financialpost.comAcerus Pharmaceuticals Announces Co-Promotion Agreement with Amneal Pharmaceuticals for NATESTO® Amneal’s U.S. based Specialty Sales Force to Begin Promoting NATESTO by July 2021, Significantly Expanding Acerus’ Commercial Footprint within Endocrinology SegmentApril 1, 2021 | financialpost.comAcerus Buys Back All Remaining U.S. Rights for NATESTO® From Aytu Acerus Assumes Full NATESTO Ownership from Aytu BioPharma, Accelerating Path to Becoming Fully Integrated Specialty Pharmaceutical CompanyOctober 27, 2020 | businesswire.comAcerus to Report Third Quarter 2020 Financial Results and Host Investor CallSee More Headlines Receive TRLPF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Acerus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address TRLPF Company Calendar Last Earnings11/05/2018Today9/27/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Pharmaceutical Preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:TRLPF CUSIPN/A CIKN/A Webwww.aceruspharma.com Phone416-679-0771FaxN/AEmployees29Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,790,000.00 Net Margins-254.66% Pretax MarginN/A Return on Equity-346.72% Return on Assets-94.54% Debt Debt-to-Equity Ratio0.64 Current Ratio1.35 Quick Ratio0.90 Sales & Book Value Annual Sales$7.38 million Price / Sales7.71 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares258,615,000Free FloatN/AMarket Cap$56.90 million OptionableNot Optionable Beta2.60 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMs. Patricia SymmesChief Operating OfficerDr. Nathan BrysonChief Scientific OfficerMr. Philippe SavardVP, Gen. Counsel & Corp. Sec.Mr. Edward GudaitisPres , CEO & DirectorMr. Robert M. MotzChief Financial OfficerKey CompetitorsAEON BiopharmaNASDAQ:AEONMinerva NeurosciencesNASDAQ:NERVRockwell MedicalNASDAQ:RMTIAdageneNASDAQ:ADAGADC TherapeuticsNYSE:ADCTView All Competitors TRLPF Stock - Frequently Asked Questions How have TRLPF shares performed in 2023? Acerus Pharmaceuticals' stock was trading at $0.5579 at the beginning of the year. Since then, TRLPF stock has decreased by 60.6% and is now trading at $0.22. View the best growth stocks for 2023 here. How were Acerus Pharmaceuticals' earnings last quarter? Acerus Pharmaceuticals Co. (OTCMKTS:TRLPF) announced its earnings results on Monday, November, 5th. The specialty pharmaceutical company reported ($0.01) EPS for the quarter, hitting the consensus estimate of ($0.01). The specialty pharmaceutical company earned $1.58 million during the quarter. Acerus Pharmaceuticals had a negative trailing twelve-month return on equity of 346.72% and a negative net margin of 254.66%. What is Acerus Pharmaceuticals' stock symbol? Acerus Pharmaceuticals trades on the OTCMKTS under the ticker symbol "TRLPF." How do I buy shares of Acerus Pharmaceuticals? Shares of TRLPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Acerus Pharmaceuticals' stock price today? One share of TRLPF stock can currently be purchased for approximately $0.22. How much money does Acerus Pharmaceuticals make? Acerus Pharmaceuticals (OTCMKTS:TRLPF) has a market capitalization of $56.90 million and generates $7.38 million in revenue each year. The specialty pharmaceutical company earns $-18,790,000.00 in net income (profit) each year or ($0.08) on an earnings per share basis. How can I contact Acerus Pharmaceuticals? Acerus Pharmaceuticals' mailing address is 2486 Dunwin Drive, Mississauga A6, L5L 1J9. The official website for the company is www.aceruspharma.com. The specialty pharmaceutical company can be reached via phone at 416-679-0771 or via email at ir@aceruspharma.com. This page (OTCMKTS:TRLPF) was last updated on 9/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acerus Pharmaceuticals Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.